OPEN END TURBO CALL WARRANT - MODERNA | Market Closed - Boerse Frankfurt Warrants 13:35:22 2024-06-28 EDT | ||
| 2.51 EUR | -9.06% |
|
| Current month | -46.71% | ||
| 1 month | -54.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-28 | 2.51 | -9.06% |
| 24-06-27 | 2.76 | -12.93% |
| 24-06-26 | 3.17 | -24.70% |
| 24-06-25 | 4.21 | +0.72% |
| 24-06-24 | 4.18 | +4.50% |
Real-time Boerse Frankfurt Warrants
Last update June 28, 2024 at 01:35 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| WKN | UM1LJ0 |
| ISIN | DE000UM1LJ03 |
| Date issued | 2024-02-28 |
| Strike | 91.93 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.53 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.33 € |
|---|---|
| Lowest since issue | 0.41 € |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Certificates
- Certificat
